AAAAAA

   
Results: 1-20 |
Results: 20

Authors: Becker, S Fisher, A Flexner, C Gerber, JG Haubrich, R Kashuba, ADM Luber, AD Piscitelli, SC
Citation: S. Becker et al., Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio:Call for consensus, J ACQ IMM D, 27(2), 2001, pp. 210-211

Authors: Eron, JJ Haubrich, R Lang, W Pagano, G Millard, J Wolfram, J Snowden, W Pedneault, L Tisdale, M
Citation: Jj. Eron et al., A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir, J ACQ IMM D, 26(5), 2001, pp. 458-461

Authors: Demeter, L Haubrich, R
Citation: L. Demeter et R. Haubrich, Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations, J ACQ IMM D, 26, 2001, pp. S3-S9

Authors: Haubrich, R Demeter, L
Citation: R. Haubrich et L. Demeter, Clinical utility of resistance testing: Retrospective and prospective datasupporting use and current recommendations, J ACQ IMM D, 26, 2001, pp. S51-S59

Authors: Schooley, RT Clumeck, N Haubrich, R Thompson, M Danner, SA van Der Ende, ME Sereni, D Antunes, F Blake, D Myers, RE Tisdale, M Millard, J Mustafa, N Nacci, P
Citation: Rt. Schooley et al., A dose-ranging study to evaluate the antiretroviral activity and safety ofamprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience, ANTIVIR TH, 6(2), 2001, pp. 89-96

Authors: McMahon, D Lederman, M Haas, DW Haubrich, R Stanford, J Cooney, E Horton, J Kelleher, D Ross, L Cutrell, A Lee, D Spreen, W Mellors, JW
Citation: D. Mcmahon et al., Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults, ANTIVIR TH, 6(2), 2001, pp. 105-114

Authors: Kemper, CA Witt, MD Keiser, PH Dube, MP Forthal, DN Leibowitz, M Smith, DS Rigby, A Hellmann, NS Lie, YS Leedom, J Richman, D McCutchan, JA Haubrich, R
Citation: Ca. Kemper et al., Sequencing of protease inhibitor therapy: insights from an analysis of HIVphenotypic resistance in patients failing protease inhibitors, AIDS, 15(5), 2001, pp. 609-615

Authors: Sadler, BM Gillotin, C Lou, Y Eron, JJ Lang, W Haubrich, R Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668

Authors: Katzenstein, DA Hughes, M Albrecht, M Hammer, S Para, M Murphy, R Valdez, H Haubrich, R Liou, S
Citation: Da. Katzenstein et al., Virologic and CD4(+) cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection, AIDS RES H, 16(11), 2000, pp. 1031-1037

Authors: Sha, BE Johnson, VA Kendall, MA Haubrich, R Nokta, M Lamb, K Zackin, RA Nail, CD Currier, JS
Citation: Be. Sha et al., Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels, AIDS, 14(6), 2000, pp. 746-748

Authors: Lederman, MM McKinnis, R Kelleher, D Cutrell, A Mellors, J Neisler, M Cooney, E Haas, DW Haubrich, R Stanford, J Horton, J Landay, A Spreen, W
Citation: Mm. Lederman et al., Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase, AIDS, 14(17), 2000, pp. 2635-2642

Authors: Fletcher, CV Acosta, EP Cheng, HL Haubrich, R Fischl, M Raasch, R Mills, C Hu, XJ Katzenstein, D Remmel, RP Gulick, RM
Citation: Cv. Fletcher et al., Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884, AIDS, 14(16), 2000, pp. 2495-2501

Authors: Moss, NE Lemp, G Bluthenthal, R Goldsmith, MA Haubrich, R Kahn, JO
Citation: Ne. Moss et al., From the cell to the community: AIDS research in California, WEST J MED, 173(2), 2000, pp. 119-121

Authors: Moss, NE Lemp, G Bluthenthal, R Goldsmith, MA Haubrich, R Kahn, JO
Citation: Ne. Moss et al., Current questions in HIV/AIDS research in California - Clinical sciences, WEST J MED, 173(2), 2000, pp. 121-124

Authors: Gulick, RM Hu, XJ Fiscus, SA Fletcher, CV Haubrich, R Cheng, HL Acosta, E Lagakos, SW Swanstrom, R Freimuth, W Snyder, S Mills, C Fischl, M Pettinelli, C Katzenstein, D
Citation: Rm. Gulick et al., Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359, J INFEC DIS, 182(5), 2000, pp. 1375-1384

Authors: Gunthard, HF Wong, JK Spina, CA Ignacio, G Kwok, S Christopherson, C Hwang, J Haubrich, R Havlir, D Richman, DD
Citation: Hf. Gunthard et al., Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy, J INFEC DIS, 181(2), 2000, pp. 522-531

Authors: Revicki, DA Swartz, C Wu, AW Haubrich, R Collier, AC
Citation: Da. Revicki et al., Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm(3), ANTIVIR TH, 4(1), 1999, pp. 35-44

Authors: Haubrich, R Thompson, M Schooley, R Lang, W Stein, A Sereni, D van der Ende, ME Antunes, F Richman, D Pagano, G Kahl, L Fetter, A Brown, DJ Clumeck, N
Citation: R. Haubrich et al., A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience, AIDS, 13(17), 1999, pp. 2411-2420

Authors: Haubrich, R Richman, D
Citation: R. Haubrich et D. Richman, Nevirapine, didanosine, and zidovudine for patients with HIV: The INCAS trial, J AM MED A, 281(2), 1999, pp. 130-131

Authors: Forthal, DN Landucci, G Haubrich, R Keenan, B Kuppermann, BD Tilles, JG Kaplan, J
Citation: Dn. Forthal et al., Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients, J INFEC DIS, 180(4), 1999, pp. 1338-1341
Risultati: 1-20 |